GNH USA

Europe — EMA

Nexpovio (Selinexor)

GNH USA supplies Nexpovio (Selinexor), a selective inhibitor of nuclear export for relapsed or refractory multiple myeloma. Request a quote for supply.

Selinexor

Request sourcing

1
Pack/s

What is Selinexor?

Selinexor, the active ingredient in Nexpovio, is a selective inhibitor of nuclear export (SINE) presented as an oral tablet for oral use. It is indicated for relapsed or refractory multiple myeloma in combination with dexamethasone and bortezomib. GNH USA supplies Nexpovio as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Selinexor used for?

Selinexor acts on malignant cells by blocking nuclear export pathways, making it a key therapy in certain blood cancers. - Relapsed or refractory multiple myeloma: improves disease control when combined with dexamethasone and bortezomib. - Relapsed or refractory diffuse large B‑cell lymphoma: used with standard chemotherapy regimens to enhance response rates. - Relapsed or refractory solid tumours (clinical investigation): evaluated in trials as part of combination strategies to overcome resistance.

What are the side effects of Selinexor?

Selinexor is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Thrombocytopenia: reduced platelet count leading to easy bruising. - Anemia: low red blood cell levels causing weakness. - Neutropenia: decreased neutrophils increasing infection risk. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing conditions. - Pulmonary embolism: blood clot in the lungs. - Tumor lysis syndrome: rapid tumour cell breakdown causing metabolic disturbances. - Hyponatremia: dangerously low sodium levels.

What precautions apply to Selinexor?

Before initiating therapy, clinicians should evaluate several safety parameters. - Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs to identify hepatic toxicity. - Evaluate infection risk: avoid use in patients with active uncontrolled infections. - Review concomitant QT‑prolonging agents: consider ECG monitoring. - Pregnancy: risk unknown; avoid unless benefits outweigh potential harm. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

What does Selinexor interact with?

Selinexor may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce Selinexor exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase toxicity risk. - QT‑prolonging drugs (e.g., amiodarone): can exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Other antineoplastic agents metabolized by CYP3A4: adjust dosing as needed. - Immunosuppressants (e.g., cyclosporine): watch for enhanced myelosuppression.

Frequently asked questions

What is Nexpovio used for?+
Nexpovio contains the active ingredient Selinexor and is approved for the treatment of relapsed or refractory multiple myeloma, typically in combination with dexamethasone and bortezomib. It is also authorized for certain aggressive lymphomas and is being studied in solid‑tumour indications as part of combination regimens.
How does Selinexor work?+
Selinexor blocks the nuclear export protein exportin‑1 (XPO1). This inhibition traps tumor‑suppressor proteins, growth regulators and apoptotic factors inside the nucleus, restoring their activity and leading to programmed cell death of cancer cells while largely sparing normal cells.
What is the usual dose of Nexpovio?+
The prescribed dose of Selinexor is individualized by the treating physician based on the patient’s disease status, prior therapies, organ function and tolerance. It is administered orally as a tablet, and the exact regimen is determined by the clinician’s assessment.
Is Nexpovio safe in pregnancy or breastfeeding?+
Safety data for Selinexor during pregnancy and lactation are limited. The drug is classified as contraindicated unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally discouraged while on therapy.
How do I order Nexpovio from GNH USA?+
To place an order, submit an enquiry on the Nexpovio product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Nexpovio compare with other multiple myeloma therapies?+
Nexpovio offers a novel mechanism—nuclear export inhibition—unlike proteasome inhibitors or immunomodulatory drugs. It is often used after patients have progressed on standard regimens, providing an additional line of therapy. While effective, its safety profile includes notable cytopenias, so clinicians balance benefits against potential hematologic toxicity.
How should Nexpovio be stored and handled?+
Store Nexpovio tablets at ambient temperature, below 25 °C, in the original blister pack. Protect the product from moisture, excessive heat and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.
How is Nexpovio given or administered?+
Nexpovio is taken orally as a whole tablet, usually on an empty stomach unless the prescriber advises otherwise. The tablet should be swallowed with water and not chewed, crushed or split, to ensure consistent absorption.
What are the most serious risks to watch for while on Nexpovio?+
Serious adverse events include severe infections, significant drops in blood cell counts (especially platelets and neutrophils), hepatic injury, cardiac arrhythmias, pulmonary embolism and tumor‑lysis syndrome. Patients should be monitored closely for signs of infection, bleeding, liver dysfunction and cardiac abnormalities.
Who should not use Nexpovio?+
Nexpovio is contraindicated in individuals with known hypersensitivity to Selinexor or any tablet excipients, those with uncontrolled active infections, severe hepatic impairment, and pregnant women unless the therapeutic benefit outweighs the risk. Caution is also advised for patients with pre‑existing cardiac conditions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Selinexor
Route
Oral Use
Manufacturer
Stemline Therapeutics B.V.
Origin
EU

Related products

Xpovio 20 mg

Xpovio 20 mg

Selinexor · 20 MG

Xpovio
TABLET
FORUS THERAPEUTICS INC.
CANADA
Nexpovio

Nexpovio

Selinexor

Stemline Therapeutics B.V.
EU
Nexpovio

Nexpovio

Selinexor

Stemline Therapeutics B.V.
EU
Nexpovio

Nexpovio

Selinexor

Stemline Therapeutics B.V.
EU